Back to Search Start Over

Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression

Authors :
Karima Amaador
Josephine M. I. Vos
Steven T. Pals
Willem Kraan
Johan A. Dobber
Monique C. Minnema
Harry R. Koene
Peter C. de Bruin
Aiko H. Zwinderman
Marie José Kersten
Hematology
Graduate School
Clinical Haematology
General Internal Medicine
AII - Cancer immunology
CCA - Cancer biology and immunology
Pathology
09 Laboratory specialisms
Epidemiology and Data Science
APH - Methodology
CCA - Cancer Treatment and Quality of Life
Source :
Amaador, K, Vos, J M I, Pals, S T, Kraan, W, Dobber, J A, Minnema, M C, Koene, H R, de Bruin, P C, Zwinderman, A H & Kersten, M J 2022, ' Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression ', Leukemia and Lymphoma, vol. 63, no. 5, pp. 1070-1079 . https://doi.org/10.1080/10428194.2021.2018584, Leukemia and Lymphoma, 63(5), 1070-1079. Informa Healthcare, Leukemia & lymphoma. Informa Healthcare
Publication Year :
2021

Abstract

Discrimination between Waldenström macroglobulinemia (WM) and marginal zone lymphoma (MZL) of the bone marrow (BM) can be difficult due to overlap in clinical, histopathologic, and immunophenotypic characteristics. We determined which characteristics can aid in the differential diagnosis of ‘gray zone’ cases. We compared clinical, histopathologic, immunophenotypic, and molecular features of 222 WM and 65 MZL patients. LASSO regression was employed for variable selection. The most distinguishing clinical features of WM compared to MZL were the presence of the B-symptom weight loss and IgM paraprotein. Histopathological findings were plasmacytoid differentiation, monoclonal plasma cells, and increased mast cells in the BM. Regarding flow cytometry, only CD10 and CD38 were distinguishing markers. Finally, as the expected presence of the MYD88L265P mutation showed to be of great value in the distinction between WM and MZL. Despite the great overlap, WM can often be distinguished from MZL by using a combination of characteristics. These characteristics should be weighed in complex, ‘gray zone’ cases.

Details

Language :
English
ISSN :
10428194
Database :
OpenAIRE
Journal :
Leukemia & lymphoma
Accession number :
edsair.doi.dedup.....09cee69aacff052cb5396507fc932130